All information in this presentation is as of the date presented, and BeiGene undertakes no duty to update such information unless required by law.

“BeiGene has demonstrated that it is possible ... during the same year a drug receives approval in the U.S,” CEO of Max, Pat Garcia-Gonzalez, remarked.

While Ideaya is letting Amgen go, it is retaining an interest in MAT2A-PRMT5 combinations. Ideaya has a PRMT5 inhibitor, ...

BeiGene is looking increasingly like it will ... At JP Morgan last month, pharmaphorum caught up with Paul Hastings, the CEO of Nkarta, to talk about NK cells and autoimmune diseases.

In a report released yesterday, Kelly Shi from Jefferies reiterated a Buy rating on BeiGene (ONC – Research Report), with a price target of $286.00. Kelly Shi’s rating is based on a ...

ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. The two companies will conduct a confirmatory randomized Phase 3 clinical ...

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced a collaboration with BeiGene Ltd., a global oncology company ...

SAN MATEO, Calif.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its fourth ...

This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding ...